Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer.

被引：1
|
作者：
Komaki, R. [1 ]
Blumenschein, G. R. [1 ]
Wistuba, I. I. [1 ]
Lee, J. J. [1 ]
Allen, P. [1 ]
Wei, X. [1 ]
Welsh, J. [1 ]
O'Reilly, M. [1 ]
Herbst, R. S. [1 ]
Tang, X. [1 ]
Meyn, R. [1 ]
Liu, D. [1 ]
Hong, W. K. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7020
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The Phase II Trial Of Erlotinib And Radiotherapy Following Chemoradiotherapy For Patients With Stage III Non-small Cell Lung Cancer Has Shown A Favorable Response Profile
    Komaki, R. U.
    Blumenschein, G. R.
    Wistuba, I. I.
    Lee, J.
    Allen, P. K.
    Wei, X.
    Welsh, J.
    O'Reilly, M. S.
    Tang, X.
    Hong, W.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S591 - S592
  • [2] Vimentin Score Predicts Resistance to Erlotinib and Radiotherapy for Patients with Stage III Non-Small Cell Lung Cancer on A Prospective Phase II Trial
    Komaki, R. U.
    Kim, Y. B.
    Wistuba, I. I.
    Tang, X. M.
    Meyn, R.
    Allen, P. K.
    Wei, X.
    O'Reilly, M. S.
    Blumenschein, G.
    Hong, W.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S330 - S330
  • [3] The Phase II Trial of Erotinib and Radiotherapy Folling Chemoradiotherapy for Patients with Stage III Non-Small Cell Lung Cancer Has Shown a Favorable Response Profile
    Komaki, R. U.
    Allen, P. K.
    Wei, X.
    Blumenschein, G. R.
    Wistuba, I. I.
    Lee, J.
    Welsh, J.
    O'Reilly, M. S.
    Tang, X. M.
    Hong, W. K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S279 - S279
  • [4] Preoperative erlotinib in clinical stage I and II non-small cell lung cancer.
    Port, J. L.
    Yankelevitz, D.
    Lee, P. C.
    Spinelli, C.
    Altorki, N. K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] A PHASE I / II TRIAL OF THE HDAC INHIBITOR BELINOSTAT IN COMBINATION WITH ERLOTINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER.
    Andersen, Jon L.
    Holm, Bente
    Rasmussen, Trine S.
    Mellemgaard, Anders
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1201 - S1202
  • [6] Vimentin (EMT Marker Protein) Score Predicts Resistance to Erlotinib and Radiotherapy for Patients with Stage III Non-Small Cell Lung Cancer on A Prospective Phase II Trial
    Komaki, R. U.
    Kim, Y. B.
    Wistuba, I. I.
    Tang, X.
    Meyn, R.
    Allen, P. K.
    Wei, X.
    Lee, J. J.
    O'Reilly, M. S.
    Hong, W. K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S220 - S220
  • [7] PHASE II TRIAL OF ERLOTINIB IN PREVIOUSLY TREATED PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Okano, Yoshio
    Shinohara, Tsutomu
    Machida, Hisanori
    Hatakeyama, Nobuo
    Takeuchi, Eiji
    Doi, Hiroyuki
    Kubota, Tetsuya
    Yokoyama, Akihito
    Ogushi, Fumitaka
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1175 - S1176
  • [8] Randomized phase II trial of radiotherapy with or without erlotinib in patients with locally advanced or unresectable non-small cell lung cancer
    Martinez, E.
    Martinez, M. T.
    de la Torre, A.
    Valcarcel, F.
    Perez, A.
    Domine, M.
    Amador, M. L.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S510 - S510
  • [9] Phase II trial of docetaxel in Asian patients with inoperable stage III non-small cell lung cancer
    Goh, BC
    Lehnert, M
    Lim, HL
    Ng, AWK
    Chan, CC
    Kong, HL
    Lee, SC
    Wee, J
    Chua, ET
    Wong, JEL
    [J]. ACTA ONCOLOGICA, 2000, 39 (02) : 225 - 229
  • [10] A Galician Lung Cancer Group phase II study: Erlotinib as maintenance therapy after concurrent chemoradiotherapy in patients (p) with stage III non-small cell lung cancer (NSCLC)
    Vazquez, S.
    Firvida, J.
    Lazaro, M.
    Baron, F. J.
    Alonso-Jaudenes Curbera, G.
    Amenedo, M.
    Santome, L.
    Afonso, F. J.
    Cardona, J. V.
    Casal, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345